Improving the Pharmacological Properties of Ciclopirox for Its Use in Congenital Erythropoietic Porphyria

• Main Authors: Ganeko Bernardo-Seisdedos, Jorge M. Charco, Itxaso SanJuan, Sandra García-Martínez, Pedro Urquiza, Hasier Eraña, Joaquín Castilla, Oscar Millet
• Format: Article
• Language: English
• Published: MDPI AG 2021-05-01
• Series: Journal of Personalized Medicine
• Subjects: ciclopirox; pharmacological chaperones; porphyria; drug discovery; protein stability
• Online Access: https://www.mdpi.com/2075-4426/11/6/485

Congenital erythropoietic porphyria (CEP), also known as Günther’s disease, results from a deficient activity in the fourth enzyme, uroporphyrinogen III synthase (UROIIIS), of the heme pathway. Ciclopirox (CPX) is an off-label drug, topically prescribed as an antifungal. It has been recently shown that it also acts as a pharmacological chaperone in CEP, presenting a specific activity in deleterious mutations in UROIIIS. Despite CPX is active at subtoxic concentrations, acute gastrointestinal (GI) toxicity was found due to the precipitation in the stomach of the active compound and subsequent accumulation in the intestine. To increase its systemic availability, we carried out pharmacokinetic (PK) and pharmacodynamic (PD) studies using alternative formulations for CPX. Such strategy effectively suppressed GI toxicity in WT mice and in a mouse model of the CEP disease (<i>UROIIIS</i>^P248Q/P248Q). In terms of activity, phosphorylation of CPX yielded good results in CEP cellular models but showed limited activity when administered to the CEP mouse model. These results highlight the need of a proper formulation for pharmacological chaperones used in the treatment of rare diseases.